Leveljump Healthcare Valuation

Is JUMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JUMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate JUMP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate JUMP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JUMP?

Key metric: As JUMP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for JUMP. This is calculated by dividing JUMP's market cap by their current revenue.
What is JUMP's PS Ratio?
PS Ratio	0.3x
Sales	CA$15.06m
Market Cap	CA$4.82m

JUMP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	102.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does JUMP's PS Ratio compare to its peers?

The above table shows the PS ratio for JUMP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.3x
PHA Premier Health of America	0.05x	4.3%	CA$7.8m
JNH Jack Nathan Medical	0.1x	n/a	CA$2.6m
ARC ARCpoint	0.8x	n/a	CA$7.7m
NPTH NeuPath Health	0.1x	n/a	CA$9.0m
JUMP Leveljump Healthcare	0.3x	n/a	CA$4.8m

Price-To-Sales vs Peers: JUMP is expensive based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.2x).

Price to Sales Ratio vs Industry

How does JUMP's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
DOC CloudMD Software & Services	0.1x	n/a	US$7.82m
NPTH NeuPath Health	0.1x	n/a	US$6.46m
PHA Premier Health of America	0.05x	4.3%	US$5.57m
BLMH Bloom Health Partners	0.1x	n/a	US$2.85m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: JUMP is good value based on its Price-To-Sales Ratio (0.3x) compared to the North American Healthcare industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is JUMP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JUMP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate JUMP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeuPath Health

CA$9.0m

Provides chronic pain management services in Canada.

NPTH

CA$0.16

3.2%

Medical Facilities

CA$369.6m

Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.

CA$15.73

4.4%

81.2%

Carebook Technologies

CA$6.2m

Engages in the development and commercialization of digital health platforms for assessments, reporting, and targeted solutions in Canada, the United States, Europe, Latin America, Asia, and internationally.

CRBK

CA$0.06

-25.0%

-14.3%